方达医药收购美国RMI实验室,扩充DMPK服务能力
Frontage Holdings Corporation ( “Frontage” or the “Group”, 1521.HK), a contract research organization (“CRO”) providing integrated, science-driven research, analytical and development services with presence in both the United States and China, today announced Frontage Laboratories, Inc.("Frontage Labs"), a wholly-owned subsidiary of the Group, entered into an equity purchase agreement with Dr. Phillip Tiller and Dr. Xiao (Sean) Yu, two independent third party individuals. According to the agreement, Frontage Labs will purchase the entire equity interest in RMI Laboratories, LLC (“RMI”) owned by the individual third parties.